



RECEIVED

DEC 31 2002


TC 1700

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: William P. Van Antwerp et al. Examiner: Unassigned
Serial No.: 10/035,831 Group Art Unit: 1762
Filed: 12/28/2001 Docket No.: 047711-0273
Title: STABILIZING CATHETER FOR PROTEIN DRUG DELIVERY

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on December 16, 2002.

By: 
Juanita Soberanis

RECEIVED
MAR 26 2003
GROUP 1700

INFORMATION DISCLOSURE STATEMENT

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

JAN 16 2003

Dear Sir:

TECH CENTER 1600/2900

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the issuance of a first Office Action in the above-identified application. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.


No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or

otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge fees, if any, to Deposit Account No. 50-0872.

Dated: 12/16/02

Respectfully submitted,
By 
Ted R. Rittmaster
Reg. No.: 32,933

FOLEY & LARDNER
2029 Century Park East
Suite 3500
Los Angeles, CA 90067-3021
Tel.: (310) 277-2223
Fax: (310) 557-8475

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 047711-0273	SERIAL NO. 10/035,831
SUPPLEMENTAL O I P INFORMATION DISCLOSURE CITATION		APPLICANT William P. Van Antwerp et al.	
		FILING DATE 12/28/2001	GROUP ART UNIT 1762
DEC 26 2002 (use several sheets if necessary)			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,702,372	12/30/1997	Nelson	604	264	02/08/1995
	A						
	A						
	A						
	A						
	A						
	A						
	A						
	A						
	A						
	A						
	A						
	A						
	A						
	A						

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B							
	B							
	B							
	B							

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Program for Plasma Polymerization/Deposition Symposium, <u>Second International Symposium on Polymer Surface Modification: Relevance to Adhesion</u> , Pages 1-12.
C2	Brian Rudie, Osmonics, <u>Hydrophilicity and Hydrophobicity</u> , Pages 1-9.
C3	Richard H. Griffey et al., Biophysical Journal/Biophysical Society, <u>Characterization of the Carbamino Adducts of Insulin</u> , Vol. 54, August 1988, Pages 295-300.
C4	Ewa Ciszak et al., Current Biology Ltd ISSN 0969-2126, <u>Role of C-Terminal B-Chain Residues in Insulin Assembly: The Structure of Hexameric Lys^{B28}Pro^{B29}-human insulin</u> , June 1995, Vol. 3 No. 6, Pages 615-622.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.